Skip to main content

SUPN

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

SUPN Price
Price Chart

Forward-looking statistics

Beta
0.77
Risk
38.97%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees665
Market cap$1.4B

Fundamentals

Enterprise value$1.3B
Revenue$668.0M
Revenue per employee—
Profit margin9.27%
Debt to equity3.13

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$1.11
Dividend per share—
Revenue per share$12.07
Avg trading volume (30 day)$19M
Avg trading volume (10 day)$23M
Put-call ratio—

Macro factor sensitivity

Growth-0.4
Credit+4.9
Liquidity+1.4
Inflation-2.5
Commodities-0.4
Interest Rates-1.4

Valuation

Dividend yield0.00%
PEG Ratio16.92
Price to sales2.68
P/E Ratio16.92
Enterprise Value to Revenue2.00
Price to book1.74

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?

Investors in Supernus Pharmaceuticals, Inc. SUPN need to pay close attention to the stock based on moves in the options market lately. That is because the June 20, 2025 $30 Call had some of the highest implied volatility of all equity options today.

Zacks Investment Research (May 14, 2025)
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

On Tuesday, Supernus Pharmaceuticals, Inc. SUPN revealed the topline data from the Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD).

Benzinga (February 19, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free